Worth reading
65In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
7040000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause)
Who receives how much
Number of shares delivered during the month: 7,040,000 shares (new shares: 7,040,000; transferred treasury shares: 0)
EVO FUND (240,000 rights)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to exercise restrictions: 7.3% (7,040,000 shares delivered across all series / 96,334,098 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise prices in July 2026 were ¥31.0, ¥30.0, ¥32.0, ¥33.0 and ¥34.0. Details of the adjustment clause and the floor price: not disclosed
Number of Stock Acquisition Rights
Total number issued: 240,000 rights; number exercised during the month: 70,400 rights; number unexercised as of the end of the preceding month: 230,000 rights; number unexercised as of the end of the month: 159,600 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
12 June 2026: Issuance of the 19th Series Stock Acquisition Rights (with exercise price adjustment clause), with EVO FUND as the allottee (total number issued: 240,000 rights), 12 June 2026: Issuance of the 2nd Series Unsecured Corporate Bonds (privately placed bonds) (amount details: not disclosed)
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 7,040,000 shares (new shares: 7,040,000; transferred treasury shares: 0) |
| Intended allottee | EVO FUND (240,000 rights) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 7.3% (7,040,000 shares delivered across all series / 96,334,098 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 97,334,098 shares (as of the end of the month preceding the month under review) → Not disclosed |
| Exercise price | Exercise prices in July 2026 were ¥31.0, ¥30.0, ¥32.0, ¥33.0 and ¥34.0. Details of the adjustment clause and the floor price: not disclosed |
| Number of Stock Acquisition Rights | Total number issued: 240,000 rights; number exercised during the month: 70,400 rights; number unexercised as of the end of the preceding month: 230,000 rights; number unexercised as of the end of the month: 159,600 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 12 June 2026: Issuance of the 19th Series Stock Acquisition Rights (with exercise price adjustment clause), with EVO FUND as the allottee (total number issued: 240,000 rights), 12 June 2026: Issuance of the 2nd Series Unsecured Corporate Bonds (privately placed bonds) (amount details: not disclosed) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of these Stock Acquisition Rights in July 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.